News 2024-08-27
Connect with Porton at CPhI Europe 2024 @ Booth 5C17
CPhI Europe (October 8-10) in Milan, Italy, stands as a worldwide event in the pharmaceutical industry, bringing together key players, thought leaders, and businesses from across the globe. At this year's exhibition, Porton will showcase its end-to-end global CDMO service capabilities across both drug substance and drug product development and manufacturing and the differentiated advantages it offers to customers. From new drug development and process optimization to commercial manufacturing, Porton is dedicated to addressing customer needs and delivering efficient CDMO solutions at the highest quality and service levels. Our expertise spans from small molecules (DS-DP) to Tides, Biologics, and Conjugates.
With more than 62,000 professionals and 2,400 exhibitors hailing from over 166 countries, CPhI Europe is celebrated as one of the world's largest pharmaceutical trade show. This event serves as an unparalleled platform for powerful networking, fostering collaborations, and driving forward the pharmaceutical sector's growth and innovation.
For onsite meeting appointments, please contact: business@portonpharma.com.
Others
More
News 2025-01-14
Successful GMP Drug Product Delivery by Porton Biologics and Conjugates Platform
Recently, the Porton Biologics and Conjugates Platform successfully completed the GMP contract manufacturing of three batches of sterile drug products for a client at our R&D and production facility in Pudong, Shanghai. This milestone marks a significant step forward for our Biologics and Conjugates CDMO platform—a testament to our unwavering commitment to quality and reliability.
News 2025-01-03
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
Porton Pharma Solutions Ltd. (hereinafter “Porton”) is glad to announce that it scored 44 (out of 100) in the 2024 S&P Global Corporate Sustainability Assessment reflecting an improvement of 6 points over the previous assessment, where scores in all the three dimensions getting improved. (CSA Score as of 27/11/2024).
